Published in J Biol Chem on May 05, 2003
The metabolic serine hydrolases and their functions in mammalian physiology and disease. Chem Rev (2011) 1.89
Antiviral prodrugs - the development of successful prodrug strategies for antiviral chemotherapy. Br J Pharmacol (2006) 1.25
Molecular basis of prodrug activation by human valacyclovirase, an alpha-amino acid ester hydrolase. J Biol Chem (2008) 1.04
The Biopharmaceutics Classification System: subclasses for in vivo predictive dissolution (IPD) methodology and IVIVC. Eur J Pharm Sci (2014) 0.95
Enhanced cancer cell growth inhibition by dipeptide prodrugs of floxuridine: increased transporter affinity and metabolic stability. Mol Pharm (2008) 0.93
Increasing oral absorption of polar neuraminidase inhibitors: a prodrug transporter approach applied to oseltamivir analogue. Mol Pharm (2013) 0.92
Chemical and enzymatic stability of amino acid prodrugs containing methoxy, ethoxy and propylene glycol linkers. Mol Pharm (2009) 0.88
Human carboxymethylenebutenolidase as a bioactivating hydrolase of olmesartan medoxomil in liver and intestine. J Biol Chem (2010) 0.87
Enhancing the intestinal absorption of molecules containing the polar guanidino functionality: a double-targeted prodrug approach. J Med Chem (2010) 0.86
An inserted α/β subdomain shapes the catalytic pocket of Lactobacillus johnsonii cinnamoyl esterase. PLoS One (2011) 0.86
Human valacyclovir hydrolase/biphenyl hydrolase-like protein is a highly efficient homocysteine thiolactonase. PLoS One (2014) 0.82
Specificity of a prodrug-activating enzyme hVACVase: the leaving group effect. Mol Pharm (2010) 0.80
Differential Mechanisms of Tenofovir and Tenofovir Disoproxil Fumarate Cellular Transport and Implications for Topical Preexposure Prophylaxis. Antimicrob Agents Chemother (2015) 0.78
Substrate-Competitive Activity-Based Profiling of Ester Prodrug Activating Enzymes. Mol Pharm (2015) 0.77
Selection of suitable prodrug candidates for in vivo studies via in vitro studies; the correlation of prodrug stability in between cell culture homogenates and human tissue homogenates. J Pharm Pharm Sci (2012) 0.76
Paraoxonases-1, -2 and -3: What are their functions? Chem Biol Interact (2016) 0.76
Puromycin-sensitive aminopeptidase: an antiviral prodrug activating enzyme. Antiviral Res (2009) 0.76
Synthesis and characterization of valyloxy methoxy luciferin for the detection of valacyclovirase and peptide transporter. Bioorg Med Chem Lett (2014) 0.75
Carrier-Mediated Prodrug Uptake to Improve the Oral Bioavailability of Polar Drugs: An Application to an Oseltamivir Analogue. J Pharm Sci (2016) 0.75
Ocular cytochrome P450s and transporters: roles in disease and endobiotic and xenobiotic disposition. Drug Metab Rev (2014) 0.75
Nanoparticles: Is Toxicity a Concern? EJIFCC (2011) 0.75
Oral drug absorption in pediatrics: the intestinal wall, its developmental changes and current tools for predictions. Biopharm Drug Dispos (2016) 0.75
Innate recognition of bacteria by a macrophage cytosolic surveillance pathway. Proc Natl Acad Sci U S A (2002) 3.85
Drug delivery strategy utilizing conjugation via reversible disulfide linkages: role and site of cellular reducing activities. Adv Drug Deliv Rev (2003) 3.25
Molecular properties of WHO essential drugs and provisional biopharmaceutical classification. Mol Pharm (2004) 2.63
Properties regulating the nature of the plasmacytoid dendritic cell response to Toll-like receptor 9 activation. J Exp Med (2006) 2.57
A specific gene expression program triggered by Gram-positive bacteria in the cytosol. Proc Natl Acad Sci U S A (2004) 2.10
A provisional biopharmaceutical classification of the top 200 oral drug products in the United States, Great Britain, Spain, and Japan. Mol Pharm (2006) 2.07
A mechanistic approach to understanding the factors affecting drug absorption: a review of fundamentals. J Clin Pharmacol (2002) 1.85
Biopharmaceutics classification system: the scientific basis for biowaiver extensions. Pharm Res (2002) 1.74
Polymer degradation and in vitro release of a model protein from poly(D,L-lactide-co-glycolide) nano- and microparticles. J Control Release (2003) 1.72
The use of BDDCS in classifying the permeability of marketed drugs. Pharm Res (2008) 1.57
Lessons learned from marketed and investigational prodrugs. J Med Chem (2004) 1.43
Summary workshop report: biopharmaceutics classification system--implementation challenges and extension opportunities. J Pharm Sci (2004) 1.43
Comparison of human duodenum and Caco-2 gene expression profiles for 12,000 gene sequences tags and correlation with permeability of 26 drugs. Pharm Res (2002) 1.37
Prediction of solubility and permeability class membership: provisional BCS classification of the world's top oral drugs. AAPS J (2009) 1.37
Accelerated macrophage apoptosis induces autoantibody formation and organ damage in systemic lupus erythematosus. J Immunol (2006) 1.28
Why is it challenging to predict intestinal drug absorption and oral bioavailability in human using rat model. Pharm Res (2006) 1.26
Amino acid ester prodrugs of the anticancer agent gemcitabine: synthesis, bioconversion, metabolic bioevasion, and hPEPT1-mediated transport. Mol Pharm (2005) 1.21
Physiological parameters for oral delivery and in vitro testing. Mol Pharm (2010) 1.18
The suitability of an in situ perfusion model for permeability determinations: utility for BCS class I biowaiver requests. Mol Pharm (2006) 1.16
Listeriolysin O-liposome-mediated cytosolic delivery of macromolecule antigen in vivo: enhancement of antigen-specific cytotoxic T lymphocyte frequency, activity, and tumor protection. Biochim Biophys Acta (2002) 1.16
The BCS, BDDCS, and regulatory guidances. Pharm Res (2011) 1.11
Pharmacokinetics of an immediate release, a controlled release and a two pulse dosage form in dogs. Eur J Pharm Biopharm (2005) 1.10
Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting. Am J Physiol Gastrointest Liver Physiol (2009) 1.08
A novel nucleoside prodrug-activating enzyme: substrate specificity of biphenyl hydrolase-like protein. Mol Pharm (2005) 1.04
Molecular basis of prodrug activation by human valacyclovirase, an alpha-amino acid ester hydrolase. J Biol Chem (2008) 1.04
Floxuridine amino acid ester prodrugs: enhancing Caco-2 permeability and resistance to glycosidic bond metabolism. Pharm Res (2005) 1.04
Targeted delivery to PEPT1-overexpressing cells: acidic, basic, and secondary floxuridine amino acid ester prodrugs. Mol Cancer Ther (2005) 1.03
Summary workshop report: bioequivalence, biopharmaceutics classification system, and beyond. AAPS J (2008) 1.01
Amino acid ester prodrugs of floxuridine: synthesis and effects of structure, stereochemistry, and site of esterification on the rate of hydrolysis. Pharm Res (2003) 1.00
Multiple efflux pumps are involved in the transepithelial transport of colchicine: combined effect of p-glycoprotein and multidrug resistance-associated protein 2 leads to decreased intestinal absorption throughout the entire small intestine. Drug Metab Dispos (2009) 1.00
Gene expression in the human intestine and correlation with oral valacyclovir pharmacokinetic parameters. J Pharmacol Exp Ther (2003) 0.99
High-permeability criterion for BCS classification: segmental/pH dependent permeability considerations. Mol Pharm (2010) 0.99
Segmental dependent transport of low permeability compounds along the small intestine due to P-glycoprotein: the role of efflux transport in the oral absorption of BCS class III drugs. Mol Pharm (2009) 0.98
Comparative gene expression profiles of intestinal transporters in mice, rats and humans. Pharmacol Res (2007) 0.98
Enhanced gene delivery using disulfide-crosslinked low molecular weight polyethylenimine with listeriolysin o-polyethylenimine disulfide conjugate. J Control Release (2008) 0.97
In vitro testing of drug absorption for drug 'developability' assessment: forming an interface between in vitro preclinical data and clinical outcome. Curr Opin Drug Discov Devel (2004) 0.97
Enhancing the intestinal membrane permeability of zanamivir: a carrier mediated prodrug approach. Mol Pharm (2011) 0.96
Blockade of interleukin-6 receptor suppresses the proliferation of H460 lung cancer stem cells. Int J Oncol (2012) 0.95
Stability of the Clostridium botulinum type A neurotoxin complex: an empirical phase diagram based approach. Mol Pharm (2007) 0.95
The solubility-permeability interplay in using cyclodextrins as pharmaceutical solubilizers: mechanistic modeling and application to progesterone. J Pharm Sci (2010) 0.95
Feasibility of biowaiver extension to biopharmaceutics classification system class III drug products: cimetidine. Clin Pharmacokinet (2006) 0.95
Differential cytosolic delivery and presentation of antigen by listeriolysin O-liposomes to macrophages and dendritic cells. Mol Pharm (2005) 0.94
Localization of protein kinase C epsilon to macrophage vacuoles perforated by Listeria monocytogenes cytolysin. Cell Microbiol (2007) 0.94
Surfactant-mediated dissolution: contributions of solubility enhancement and relatively low micelle diffusivity. J Pharm Sci (2004) 0.94
Grapefruit juice and its constituents augment colchicine intestinal absorption: potential hazardous interaction and the role of p-glycoprotein. Pharm Res (2008) 0.94
Enhanced cancer cell growth inhibition by dipeptide prodrugs of floxuridine: increased transporter affinity and metabolic stability. Mol Pharm (2008) 0.93
Enabling the intestinal absorption of highly polar antiviral agents: ion-pair facilitated membrane permeation of zanamivir heptyl ester and guanidino oseltamivir. Mol Pharm (2010) 0.93
Tacrolimus is a class II low-solubility high-permeability drug: the effect of P-glycoprotein efflux on regional permeability of tacrolimus in rats. J Pharm Sci (2002) 0.93
Stability of valacyclovir: implications for its oral bioavailability. Int J Pharm (2006) 0.92
A novel high-throughput pepT1 transporter assay differentiates between substrates and antagonists. Mol Pharm (2004) 0.92
Human jejunal permeability of cyclosporin A: influence of surfactants on P-glycoprotein efflux in Caco-2 cells. Pharm Res (2003) 0.92
The biowaiver extension for BCS class III drugs: the effect of dissolution rate on the bioequivalence of BCS class III immediate-release drugs predicted by computer simulation. Mol Pharm (2010) 0.92
Nucleoside ester prodrug substrate specificity of liver carboxylesterase. J Pharmacol Exp Ther (2005) 0.92
Increasing oral absorption of polar neuraminidase inhibitors: a prodrug transporter approach applied to oseltamivir analogue. Mol Pharm (2013) 0.92
Enhanced absorption and growth inhibition with amino acid monoester prodrugs of floxuridine by targeting hPEPT1 transporters. Molecules (2008) 0.92
Permeability dominates in vivo intestinal absorption of P-gp substrate with high solubility and high permeability. Mol Pharm (2005) 0.91
Mechanistic understanding of time-dependent oral absorption based on gastric motor activity in humans. Eur J Pharm Biopharm (2008) 0.90
The solubility-permeability interplay: mechanistic modeling and predictive application of the impact of micellar solubilization on intestinal permeation. Mol Pharm (2011) 0.89
Tumor cell killing enabled by listeriolysin O-liposome-mediated delivery of the protein toxin gelonin. J Biol Chem (2003) 0.89
Segmental-dependent membrane permeability along the intestine following oral drug administration: Evaluation of a triple single-pass intestinal perfusion (TSPIP) approach in the rat. Eur J Pharm Sci (2008) 0.89
Amino acid ester prodrugs of the antiviral agent 2-bromo-5,6-dichloro-1-(beta-D-ribofuranosyl)benzimidazole as potential substrates of hPEPT1 transporter. J Med Chem (2005) 0.88
Chemical and enzymatic stability of amino acid prodrugs containing methoxy, ethoxy and propylene glycol linkers. Mol Pharm (2009) 0.88
Solubilization and dissolution of insoluble weak acid, ketoprofen: effects of pH combined with surfactant. Eur J Pharm Sci (2006) 0.88
Purely in silico BCS classification: science based quality standards for the world's drugs. Mol Pharm (2013) 0.88
Feasibility studies of utilizing disk intrinsic dissolution rate to classify drugs. Int J Pharm (2004) 0.87
Amino acid ester prodrugs of 2-bromo-5,6-dichloro-1-(beta-D-ribofuranosyl)benzimidazole enhance metabolic stability in vitro and in vivo. J Pharmacol Exp Ther (2005) 0.87
Enhancing the intestinal absorption of molecules containing the polar guanidino functionality: a double-targeted prodrug approach. J Med Chem (2010) 0.86
Comparison of the permeability of metoprolol and labetalol in rat, mouse, and Caco-2 cells: use as a reference standard for BCS classification. Mol Pharm (2013) 0.86
Enhanced in vivo gene expression mediated by listeriolysin O incorporated anionic LPDII: Its utility in cytotoxic T lymphocyte-inducing DNA vaccine. J Control Release (2010) 0.86
The fraction dose absorbed, in humans, and high jejunal human permeability relationship. Mol Pharm (2012) 0.86
Cytosolic delivery of viral nucleoprotein by listeriolysin O-liposome induces enhanced specific cytotoxic T lymphocyte response and protective immunity. Mol Pharm (2004) 0.86
Quasi-equilibrium analysis of the ion-pair mediated membrane transport of low-permeability drugs. J Control Release (2009) 0.85
Role of the murine organic anion-transporting polypeptide 1b2 (Oatp1b2) in drug disposition and hepatotoxicity. Mol Pharmacol (2008) 0.85
Comparative gene expression of intestinal metabolizing enzymes. Biopharm Drug Dispos (2009) 0.84
MRP2 mediated drug-drug interaction: indomethacin increases sulfasalazine absorption in the small intestine, potentially decreasing its colonic targeting. Int J Pharm (2009) 0.84
The H2 receptor antagonist nizatidine is a P-glycoprotein substrate: characterization of its intestinal epithelial cell efflux transport. AAPS J (2009) 0.83
A fluorescent hPept1 transporter substrate for uptake screening. Pharm Res (2003) 0.83
Toward an in vivo dissolution methodology: a comparison of phosphate and bicarbonate buffers. Mol Pharm (2009) 0.83
The low/high BCS permeability class boundary: physicochemical comparison of metoprolol and labetalol. Mol Pharm (2014) 0.83
Intestinal metabolism promotes regional differences in apical uptake of indinavir: coupled effect of P-glycoprotein and cytochrome P450 3A on indinavir membrane permeability in rat. J Pharmacol Exp Ther (2002) 0.83
In silico prediction of drug dissolution and absorption with variation in intestinal pH for BCS class II weak acid drugs: ibuprofen and ketoprofen. Biopharm Drug Dispos (2012) 0.82
Drug targeting strategies for the treatment of inflammatory bowel disease: a mechanistic update. Expert Rev Clin Immunol (2010) 0.82
Possibility of enterohepatic recycling of ketoprofen in dogs. Int J Pharm (2007) 0.81
Encapsulating immunostimulatory CpG oligonucleotides in listeriolysin O-liposomes promotes a Th1-type response and CTL activity. Mol Pharm (2012) 0.81
N-methylpurine DNA glycosylase and 8-oxoguanine dna glycosylase metabolize the antiviral nucleoside 2-bromo-5,6-dichloro-1-(beta-D-ribofuranosyl)benzimidazole. Drug Metab Dispos (2006) 0.81
Transporter and ion channel gene expression after Caco-2 cell differentiation using 2 different microarray technologies. AAPS J (2004) 0.81
Mechanistic analysis of solute transport in an in vitro physiological two-phase dissolution apparatus. Biopharm Drug Dispos (2012) 0.81
Specificity of a prodrug-activating enzyme hVACVase: the leaving group effect. Mol Pharm (2010) 0.80
Interferon-gamma increases expression of the di/tri-peptide transporter, h-PEPT1, and dipeptide transport in cultured human intestinal monolayers. Pharmacol Res (2008) 0.80
Targeting and blocking B7 costimulatory molecules on antigen-presenting cells using CTLA4Ig-conjugated liposomes: in vitro characterization and in vivo factors affecting biodistribution. Pharm Res (2003) 0.79
Conjugation of lipid and CpG-containing oligonucleotide yields an efficient method for liposome incorporation. Bioconjug Chem (2011) 0.79